Human TREM1 Stable Cell Line-CHO-S

The human TREM1 gene, located on chromosome 6p21.1, encodes a transmembrane glycoprotein receptor belonging to the immunoglobulin superfamily, also designated as CD354 or TREM-1. This receptor is predominantly expressed on neutrophils, monocytes, and macrophages, where it functions as a critical amplifier of innate immune responses. Upon engagement with its ligands, TREM1 associates with the adaptor protein DAP12 to trigger downstream signaling cascades that promote the release of pro-inflammatory mediators including TNF-α, IL-8, and IL-1β. The Human TREM1 Stable Cell Line-CHO-S is generated by stably transfecting the suspension-adapted CHO-S cell line with a full-length human TREM1 expression construct, resulting in consistent, high-level surface presentation of the receptor. This engineered cell line maintains stable TREM1 expression over extended passages, providing a reliable and reproducible in vitro platform for studying TREM1 biology.

This cell product serves a broad range of research and drug discovery applications. It is particularly valuable for screening and characterizing therapeutic antibodies, small molecule inhibitors, or biologic candidates targeting TREM1, which has emerged as a promising target in inflammatory diseases, sepsis, and certain cancers. The stable cell line enables ligand-receptor binding assays, flow cytometry-based validation, and functional studies evaluating TREM1-mediated signaling and activation. Researchers can use it to assess antibody specificity, affinity, and blocking activity, or to investigate TREM1 interactions with its natural ligands and downstream effectors. The CHO-S background minimizes cross-reactivity with endogenous myeloid receptors, ensuring data clarity. Additionally, this cell line supports the development of bispecific antibodies, antibody-drug conjugates, and immunomodulatory therapies aimed at modulating TREM1 activity in infectious and autoimmune conditions.